Expanding into the European Union market can be a transformative growth opportunity for U.S. manufacturers. With more than 440 million consumers across 27 Member States, the EU offers scale, stability, and global credibility.
However, it also operates under a fundamentally different regulatory framework than the U.S. and common mistakes made by US manufacturers may delay otherwise well-planned market-entry strategies.
Understanding these mistakes can help manufacturers approach EU expansion with greater clarity and confidence.
Mistake 1: Assuming ‘510(k) Substantial Equivalence’ is equal to ‘EU MDR Equivalence’
The 510(k) route to FDA clearance allows manufacturers to demonstrate that a new medical device is substantially equivalent (SE) to a legally marketed U.S. predicate device, allowing market clearance.
Under the EU MDR, an equivalence claim allows a manufacturer to rely on clinical data from an equivalent CE-marked device instead of conducting its own clinical investigation.
While in some cases it is reasonable for a US manufacturer to rely on the same device for both substantial equivalence and an EU MDR equivalence claim, it is important to determine whether the equivalent device in question has sufficient clinical evidence to support a CE-mark submission.
In addition, the 510(k) route places emphasis on the technical similarities between the device under evaluation and the predicate device, while an EU MDR equivalence claim involves a structured comparison of technological, clinical and biological characteristics.
The manufacturer needs to have sufficient access to equivalent device information in order to substantiate an equivalence claim.
Mistake 2: Underestimating the importance of the Clinical Evaluation
A mandatory EU MDR requirement is the Clinical Evaluation Report (CER) which is a central part of the submission. It brings together data from literature, clinical investigations, and PMS activities to demonstrate that the device is safe, performs as intended and delivers a clear clinical benefit.
It is required and applied across all device classes, unlike in the U.S. where the level of clinical evidence required can vary depending on the regulatory pathway and device classification.
Under the MDR, a Clinical Evaluation is not static. The CER is a living document that must be maintained and updated throughout the device lifecycle as new data becomes available. This is a shift for manufacturers more familiar with FDA pathways such as De Novo or PMA, where clinical evidence is often more focused on the premarket stage.
In practice, the issue is rarely the absence of data, but rather how well the data is evaluated or justified. Industry guidance consistently highlights that deficiencies in CERs are amongst the most common reasons for Notified Body non-conformities.
Rather than treating the CER as a documentation exercise, manufacturers should adopt a forward-looking clinical strategy that anticipates gaps and post-market requirements.
Mistake 3: Labelling and language obligations
Language and labelling obligations are another area where U.S. manufacturers frequently underestimate the complexity of EU compliance.
Unlike the U.S., where English labelling typically suffices nationwide, the EU requires product information to be provided in the official language or languages of each Member State in which the product is marketed. This requirement can affect instructions for use, safety warnings, packaging, labelling elements, and sometimes even digital interfaces.
Selling into multiple EU countries may therefore require multiple localised versions of documentation. Failure to plan for translation and localisation can result in non-compliance findings even when the underlying product meets technical requirements.
The EU MDR also places broader expectations on what the labelling must include. This extends beyond basic product information to cover symbols, detailed instructions for use, and compliance with harmonised standards. Standardised symbols, as defined in ISO 15233-1 and EN-ISO 20417 are widely used and can reduce the need for a full text translation, although they must still be applied correctly and consistently. In the U.S., symbols are permitted but generally need to be explained within accompanying documentation.
The Unique Device Identification (UDI) system adds another layer of complexity. While both the EU and FDA require UDI, the EU framework is tied to EUDAMED and wider traceability requirements across multiple markets. This creates additional coordination challenges, particularly when managing labelling across different countries.
Failure to plan for translation, symbol use and UDI implementation can result in compliance issues, even if the device meets technical requirements.
Mistake 4: Failure to appoint an EU Authorised Representative
A fourth common mistake is failing to appoint the correct EU-based economic operator. Under the EU MDR, non-EU manufacturers must designate a single Authorised Representative established within the EU before placing the device on the market.
It is important to note that the Authorised Representative is not a formality. The role carries defined regulatory responsibilities, including verifying technical documentation, cooperating with competent authorities, and acting as a point of contact for regulatory matters. This is a legal requirement under the MDR and must be clearly established and documented.
Without a valid Authorised Representative in place, devices cannot be legally placed on the EU market. Products may be stopped at the border, removed from distribution, or be subject to enforcement action. It is important for this requirement to be in place early, as a part of the overall market entry strategy, rather than addressed once products are ready to ship.
Mistake 5: Underestimation of Post-Market Surveillance
Many U.S. manufacturers approach EU compliance as a one-time certification, but under the MDR, regulatory responsibility continues long after the CE-mark is obtained.
Post-Market Surveillance (PMS) is a structured, ongoing obligation that requires active monitoring of device performance and safety, reporting incidents, maintaining traceability, and updating technical documentation. Unlike the U.S., where post-market reporting is often reactive and focused on serious adverse events, the EU framework is prescriptive and expects continuous oversight.
Post-Market Clinical Follow-up (PMCF) is a key element of that oversight. PMCF is a proactive process for collecting and evaluating clinical data on a device after it is on the market. The purpose is to confirm that the device continues to be safe, perform as intended, and provides clinical benefit throughout its lifecycle.
Failing to implement PMS and PMCF correctly can lead to regulatory action, interruptions in supply, or challenges during Notified Body audits, as the MDR treats post-market obligations as an integral part of compliance.
Take-home message
Successfully entering the EU market requires a lot more than just meeting technical standards. Manufacturers who plan early, address EU-specific gaps, and integrate regulatory obligations into everyday operations are far more likely to avoid delays and maintain market access.
Understanding these common mistakes and taking preemptive measures will give U.S. manufacturers the clarity and confidence to navigate the EU market and build a solid foundation for growth.
Ready to move from FDA-cleared to CE-marked? Our US to Europe Market Access Program is a complete end-to-end service that leverages your existing FDA approvals to accelerate EU market entry — with a dedicated team handling strategy, clinical evidence, Notified Body submission, and ongoing PMS. Find out if you qualify.
